Skip to main content
Clinical Trials/NCT02886806
NCT02886806
Completed
Phase 1

Fully Automated Anesthesia, Analgesia and Fluid Management Using Multiple Physiologic Closed-Loop Systems in High-Risk Vascular Surgery: a Pilot Study

Erasme University Hospital1 site in 1 country13 target enrollmentOctober 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
General Anesthetic Drug Overdose
Sponsor
Erasme University Hospital
Enrollment
13
Locations
1
Primary Endpoint
The percentage of adequate anesthesia defined as a BIS between between 40 and 60, a SVV < 13% and/or cardiac index > 2.5 litre/min/m² for more/equal of 85% of the surgical time
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Evaluate the feasibility and quality of automated anesthesia, analgesia and fluid management based on a combination of several physiological variables (bispectral index [BIS], stroke volume [SV], and stroke volume variation [SVV]) using 2 independent physiologic closed-loop systems (PCLS) in patients undergoing high risk vascular surgery

Detailed Description

Evaluate the feasibility and quality of automated anesthesia, analgesia and fluid management based on a combination of several physiological variables (bispectral index \[BIS\], stroke volume \[SV\], and stroke volume variation \[SVV\]) using 2 independent physiologic closed-loop systems (PCLS) in patients undergoing high risk vascular surgery. All patients will receive total intravenous anesthesia in target controlled infusion mode using the population pharmacokinetic sets of Schnider for propofol and Minto for remifentanil to target the effect-site concentration. Infusion Toolbox 95 version 4.11 software (Free University of Brussels, Brussels, Belgium) implemented in a personal computer serving as a platform for: calculating effect-site concentrations of propofol and remifentanil; displaying effect-site concentration estimates in real time; providing a user interface that permits entry of patients' demographic data (sex, age, weight, and height) and modifications to target concentrations; controlling the propofol and remifentanil infusion pumps (Alaris Medical, Hampshire, United Kingdom); and recording calculated effect-site drug concentrations. All patients will receive a baseline crystalloid infusion (PlasmaLyte, Baxter, Belgium) delivered by a pump at a rate of 3 mL/ kg/h (Fresenius Kabi, Belgium). Additional fluid was given using a goal-directed fluid therapy protocol guided by the cardiac output monitor (EV-1000; Edwards Lifesciences) and consisted of 100 mL boluses (Voluven, Fresenius Kabi, Germany) delivered by our PCLS (Learning Intravenous Resuscitator \[LIR\]). For fluid output, a Q-Core Sapphire Multi-Therapy Infusion Pump (Q-Core, Israel) was controlled by the LIR using software provided by Q-Core via a serial connection (Commands Server R.01). If hypotension occurred (defined as mean arterial pressure \<20% of baseline blood pressure) and no fluid is delivered by the LIR, it will be treated by the anesthesiologist using a vasopressor drug. In this pilot study, each closed loop also will operate independently, guided only by its own respective inputs (BIS for the propofol; SV and SVV for the fluid boluses). The investigators will also measure analgesia using the PhysioDoloris monitoring device (MDoloris Medical Systems, Lille, France).

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
January 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Erasme University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Luc Barvais

Professor and head of the cardiothoracic and vascular anesthesia Clinics

Erasme University Hospital

Eligibility Criteria

Inclusion Criteria

  • patients scheduled for high risk vascular surgery
  • Patients American Society Anesthesiologist classification: 3 or 4

Exclusion Criteria

  • age less than 18 years,
  • patients with arrhythmias like atrial fibrillation
  • allergy to latex, propofol, remifentanil, morphine, muscle relaxant or any of the excipients,
  • pregnant woman
  • combined general and regional anesthesia,

Outcomes

Primary Outcomes

The percentage of adequate anesthesia defined as a BIS between between 40 and 60, a SVV < 13% and/or cardiac index > 2.5 litre/min/m² for more/equal of 85% of the surgical time

Time Frame: at time of surgery

Secondary Outcomes

  • performance of the closed-loop system(at time of surgery)
  • Drug consumption: propofol dose(at time of surgery)
  • number of automatic modifications of the propofol and remifentanil concentrations(at time of surgery)
  • number of patients movements(at time of surgery)
  • Occurrence of burst suppression(at time of surgery)
  • Drug consumption: remifentanil dose(at time of surgery)
  • number of hemodynamic abnormalities requiring treatment(at time of surgery)
  • time to tracheal extubation(at time of surgery)
  • Need for anesthetist interventions over the system during the surgery(at time of surgery)
  • amount of fluid given(at time of surgery)
  • intraoperative awareness(postoperative day 1 or 2)
  • Interactions between both closed-loop system during the intraoperative period especially during hypotension episodes(at time of surgery)

Study Sites (1)

Loading locations...

Similar Trials